In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp

Dubois, Jacques; Joly, J

doi:10.1093/jac/30.suppl_a.77

Cited by 17 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bacteroides fragilis group 22, 40-42 2.0-32.0 Clostridium sp 40,42 1.0-2.0 Fusobacterium sp [40][41][42] 0.13-2.0 Peptostreptococcus sp 38,40 1.0-2.0 Veillonella sp 47 32.0 Atypical Legionella pneumophila 37-39 0.25-1.0 Mycoplasma pneumoniae [33][34][35][36] 0.03-0.1 Chlamydia pneumoniae 36 0.12-1.0 µg/ml). [37][38][39] Against five isolates of Chlamydia pneumoniae, MICs are reported as 2 µg/ml. 36…”

Section: Inhibitory Activity Of Quinupristin-dalfopristinmentioning

confidence: 99%

Quinupristin‐Dalfopristin: An Overview

et al. 2000

View full text Add to dashboard Cite

Synercid (RP 59500), the first injectable streptogramin antibiotic, is composed of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin. Individually, each component has bacteriostatic activity against staphylococci and streptococci, but together, the agents exhibit synergy, leading to bactericidal activity. The combination drug, however, is bacteriostatic against Enterococcus faecium and has poor activity against Enterococcus faecalis. Despite a short half-life, an extended postantibiotic effect allows the agent to be dosed every 8-12 hours. Both drugs are largely hepatically metabolized and excreted in bile. Although not metabolized by cytochrome P450 3A4, quinupristin-dalfopristin can inhibit agents that are metabolized through this pathway. Dosage adjustments may be necessary in patients with hepatic dysfunction. Alterations in renal function have minimal effects on the agent's pharmacokinetics. Adverse events include arthralgia, myalgias, and infusion-related pain. Based on available data, quinupristin-dalfopristin appears to have a role in treating severely ill patients with infections due to multiresistant gram-positive pathogens.

show abstract

Section: Inhibitory Activity Of Quinupristin-dalfopristinmentioning

confidence: 99%

Quinupristin‐Dalfopristin: An Overview

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Rifampin is used in combination with other drugs in severe or refractory cases of legionellosis (13). In a number of comparative studies, it was the most active drug tested (6,10,24). In the present study, 90% of isolates were inhibited at concentrations of 0.008 g/ml with the larger inoculum.…”

mentioning

confidence: 51%

Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro

Schülin

Wennersten

Ferraro

et al. 1998

Antimicrob Agents Chemother

107

View full text Add to dashboard Cite

The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC 90 s], <0.008 g/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC 90 s, 0.03 to 0.06 g/ml) were more active than erythromycin A or roxithromycin. The MIC 90 s of dalfopristin-quinupristin and linezolid were 0.5 and 8 g/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.

show abstract

“…in vitro. 1,2 The purpose of this study was to examine the in-vitro activity of the oral streptogramin, RPR 106972, against Legionella spp. Our first objective was to determine if RPR 106972 was as active as erythromycin against clinical isolates of Legionella spp.…”

Section: Introductionmentioning

confidence: 99%

In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp

Pendland

Killian

Woodward

et al. 1997

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

The in-vitro activity of RPR 106972, a new oral streptogramin, was compared with that of erythromycin, ciprofloxacin, and rifampicin against 45 Legionella spp. While rifampicin was the most active of all agents tested, RPR 106972 demonstrated activity comparable to that of erythromycin and ciprofloxacin. Usually, indifference was seen when RPR 106972 was tested in combination with rifampicin or ciprofloxacin.

show abstract

In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp

Cited by 17 publications

References 0 publications

Quinupristin‐Dalfopristin: An Overview

Quinupristin‐Dalfopristin: An Overview

Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro

In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp

Contact Info

Product

Resources

About